Who Owns Aardvark Therapeutics Stock?
NASDAQ: AARDHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Ownership breakdown
- Held by institutions
- 52.60%
- Held by insiders
- 15.77%
- Institutional holders
- 93
- Institutions 52.6%
- Insiders 15.8%
- Public and other 31.6%
Who owns Aardvark Therapeutics stock?
Institutional investors own about 52.6% of Aardvark Therapeutics's shares, spread across 93 institutions that file 13F reports. That level of institutional ownership is moderate. Insiders, including executives, directors and large founding shareholders, hold 15.77% of AARD.
The largest institutional holders are Decheng Capital LLC (17.90%), Citadel Advisors Llc (5.86%) and Laurion Capital Management, LP (4.73%). Together, the top 10 institutions control 38.5% of shares outstanding. In their latest filings, 5 of the top 10 institutions increased their AARD positions and 2 reduced them.
Summary generated from market data by MetaCap's automated system. Methodology
Top institutional holders of AARD
| Institution | Shares | % Held | Change |
|---|---|---|---|
| Decheng Capital LLC | 3.92M | 17.90% | 0.0% |
| Citadel Advisors Llc | 1.28M | 5.86% | +3.3% |
| Laurion Capital Management, LP | 1.03M | 4.73% | 0.0% |
| Vanguard Capital Management LLC | 562.88K | 2.57% | +1.6% |
| AQR Capital Management, LLC | 480.25K | 2.19% | +257.1% |
| EcoR1 Capital, LLC | 396.19K | 1.81% | +100.0% |
| Adage Capital Partners GP L.L.C. | 300.00K | 1.37% | 0.0% |
| Blackrock Inc. | 187.04K | 0.85% | -76.4% |
| Geode Capital Management, LLC | 149.84K | 0.68% | -51.6% |
| Cantor Fitzgerald, L.P. | 116.58K | 0.53% | +74.8% |
% held is the share of total shares outstanding. Change is the percentage change in the position since the holder's previous 13F filing.
Top mutual fund and ETF holders of AARD
| Fund | Shares | % Held |
|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 408.67K | 1.87% |
| VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 140.39K | 0.64% |
| iShares Trust-iShares Biotechnology ETF | 94.15K | 0.43% |
| VANGUARD SCOTTSDALE FUNDS-Vanguard Russell 2000 Index Fund | 64.98K | 0.30% |
| Fidelity Concord Street Trust-Fidelity Extended Market Index Fund | 64.83K | 0.30% |
| iShares Trust-iShares Micro-Cap ETF | 44.76K | 0.20% |
| Fidelity Concord Street Trust-Fidelity Total Market Index Fund | 22.63K | 0.10% |
| ALPS ETF TRUST-ALPS Medical Breakthroughs ETF | 22.44K | 0.10% |
| Fidelity Concord Street Trust-Fidelity Series Total Market Index Fund | 18.73K | 0.09% |
| Fidelity Concord Street Trust-Fidelity Nasdaq Composite Index Fund | 15.48K | 0.07% |
Frequently asked questions
Who is the largest shareholder of Aardvark Therapeutics?
Decheng Capital LLC is the largest institutional shareholder of AARD, owning 17.90% of shares outstanding (3.92M shares) as of its latest 13F filing.
What percentage of Aardvark Therapeutics is owned by institutions?
Institutions own about 52.6% of AARD shares and 62.5% of the public float.
How much of Aardvark Therapeutics do insiders own?
Insiders, such as officers and directors, own about 15.77% of AARD shares outstanding.
Where does institutional ownership data come from?
Investment managers with more than $100 million in US equities must file Form 13F with the SEC within 45 days of each quarter-end. Holdings are therefore up to about 4.5 months old when published.